Boehringer Ingelheim Plans Biopharmaceuticals Facility in China
Facility will use mammalian cell-culture technology and be ready for operations by 2016.
Boehringer Ingelheim signed an alliance agreement and contract to build a cGMP biopharmaceuticals facility with Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base Company) in Pudong, Shanghai, the company announced in a press release. The new site will provide a full range of development and clinical services to Chinese and multinational customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China using mammalian cell-culture technology, the company claimed.
The facility will include technical process development and cGMP manufacturing and will be ready for operation in early 2016. “Our partnership with ZJ Base Company is an important step in our global China strategy as it opens a further opportunity for Boehringer Ingelheim to participate in the growing demand for high-quality biopharmaceuticals in China,” stated Christian Boehringer, chairman of the Shareholders Committee, in the press release.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
